Home
About
Pricing
Log In
Back
BITR

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Biotron Limited

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Growth

7 months capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

7
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Biotron Limited - Rights - Applications Close 01-Apr-2025

πŸ“ˆ Performance

Price History

0.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in BITR

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in BITR

N/A
BITR investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in BITR also invest in...

Biotron Limited

BIT

Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The firm has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The firm also has a portfolio of preclinical antiviral programs.

πŸ™Œ Performance (5Yr p.a)

-19.33%

πŸ“Š Share price

$0.00 AUD

🧬 BIOTECHNOLOGY

Find Out More

Kogan.com Ltd. engages in the business of a portfolio of retail and services. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2016-07-07. The Company’s businesses include Kogan Retail, Kogan Marketplace, Kogan Mobile, Kogan Internet, Kogan Insurance, Kogan Money, Kogan Energy, Kogan Travel, Dick Smith, Matt Blatt, Mighty Ape and Brosa. Its segments include Kogan.com and Mighty Ape. Kogan.com segment is an online retailer selling in-house and third-party brand household and consumer electronics products, as well as providing services for telecommunication, Internet, insurance, home finances, utilities, vehicles and travel. The Mighty Ape segment is an online specialist retailer of gaming and entertainment products. Its offering comprises products released under Kogan.com’s brands, such as Kogan, Ovela, Fortis, Certa and Komodo, and products sourced from imported and domestic third party brands such as Apple, Canon, Swann, and Samsung. The company trades through various channels, including the Kogan.com Website and Apps and the Dick Smith Website.

πŸ™Œ Performance (5Yr p.a)

-16.66%

πŸ“Š Share price

$3.44 AUD

πŸ›οΈ CONSUMER

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8332.1m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

πŸ™Œ Performance (5Yr p.a)

9.37%

πŸ“Š Share price

$147.69 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

17.44%

πŸ“Š Share price

$150.38 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

8.78%

πŸ“Š Share price

$110.13 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

🧱 MATERIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

πŸ“Š Share price

$0.00 AUD

πŸ“Š Share price

$0.00 AUD